These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 948803)
41. [Levodopa as a single treatment of Parkinsonism. Long-term control of 24 cases with discrimination analysis]. Borromei A; Manzini A Minerva Med; 1974 Nov; 65(79):4160-70. PubMed ID: 4610450 [No Abstract] [Full Text] [Related]
42. [Treatment of peptic ulcer with the anabolic steroid retabolit]. Gandziev KhE; Mizamudinov ShM Vrach Delo; 1974 Mar; (3):76-9. PubMed ID: 4468673 [No Abstract] [Full Text] [Related]
43. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)]. Ulm G Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619 [No Abstract] [Full Text] [Related]
44. The sixth year after L-dopa: quality of life and insights derived. Boshes B; Arbit J; Dolkart M; Blonsky ER; Kovach JW Trans Am Neurol Assoc; 1975; 100():166-8. PubMed ID: 1226599 [No Abstract] [Full Text] [Related]
45. Parkinson's disease: progression and mortality in the L-DOPA era. Di Rocco A; Molinari SP; Kollmeier B; Yahr MD Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142 [No Abstract] [Full Text] [Related]
46. [The use of antioxidants in the combined treatment of patients with peptic ulcer]. Chumak PIa; Redchits IV; Kachura GA; Ligonenko AV; Selikhova LG Vrach Delo; 1989 Dec; (12):53-4. PubMed ID: 2629277 [No Abstract] [Full Text] [Related]
47. [Use of Levadial in the treatment of ulcer disease]. Campesato A Minerva Gastroenterol; 1975; 21(3):155-60. PubMed ID: 1103006 [No Abstract] [Full Text] [Related]
48. [Experiences in the treatment of Parkinsonism using a combination of L-dopa and alpha-methyldopa-hydrazine]. Vymazal J; Roth B; Nevsímal O Cesk Neurol Neurochir; 1976 Mar; 39(2):59-62. PubMed ID: 1260921 [No Abstract] [Full Text] [Related]
50. Enteric-coated L-dopa (prodopa). A new approach to L-dopa therapy in Parkinson's disease. Gilligan B; Hancock R Med J Aust; 1975 Nov; 2(22):824-6. PubMed ID: 1207582 [TBL] [Abstract][Full Text] [Related]
51. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)]. Meco G; Casacchia M; Zamponi A; Agnoli A Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900 [No Abstract] [Full Text] [Related]
52. [Therapeutic experiences with a slow-release preparation of L-dopa (Madopar "HBS") in patients with advanced Parkinson disease]. Poewe W; Kleedorfer B; Gerstenbrand F Nervenarzt; 1989 May; 60(5):294-8. PubMed ID: 2739822 [No Abstract] [Full Text] [Related]
53. [Treatment of peptic ulcer with alanton]. Luchkova MM Vrach Delo; 1978 Jun; (6):69-71. PubMed ID: 695477 [No Abstract] [Full Text] [Related]
54. [Treatment of gastroduodenal ulcer with plasmutan]. Berard E; Gallavardin M Med Chir Dig; 1975; 4(1):57-60. PubMed ID: 1160427 [No Abstract] [Full Text] [Related]
55. [The drug prophylaxis of peptic ulcer exacerbations]. Grigor'ev PIa; Iakovenko EP; Agafonova NA; Prianishnikova AS; Soluianova IP; Iakovenko AV; Vasil'ev IV; Agrba VZ; Stepanov AV; Kolodkin AM Ter Arkh; 1995; 67(2):26-9. PubMed ID: 7725253 [TBL] [Abstract][Full Text] [Related]
56. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease. Shif M; Kempster PA Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663 [TBL] [Abstract][Full Text] [Related]